The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper

Bousquet, P J; Brozek, J; Bachert, C; Bieber, T; Bonini, S; Burney, P; Calderon, M; Canonica, G W; Compalati, E; Daures, J P; Delgado, L; Demoly, P; Dahl, R; Durham, S R; Kowalski, M L; Malling, H J; Merk, H; Papadopoulos, N; Passalacqua, G; Simon, H U; ... (2009). The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy, 64(12), pp. 1737-45. Oxford: Wiley-Blackwell 10.1111/j.1398-9995.2009.02232.x

Full text not available from this repository. (Request a copy)

The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen-specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo-controlled Phase III studies in this article. Our analysis focuses on the definition of patients' inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology

UniBE Contributor:

Simon, Hans-Uwe








Factscience Import

Date Deposited:

04 Oct 2013 15:10

Last Modified:

05 Dec 2022 14:21

Publisher DOI:


PubMed ID:


Web of Science ID:


URI: (FactScience: 194986)

Actions (login required)

Edit item Edit item
Provide Feedback